Immunocore Holdings Ltd
$ 32.82
-1.32%
10 Feb - close price
- Market Cap 1,658,408,000 USD
- Current Price $ 32.82
- High / Low $ 33.80 / 32.50
- Stock P/E N/A
- Book Value 7.86
- EPS -0.58
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.08 %
- 52 Week High 40.71
- 52 Week Low 23.15
About
Immunocore Holdings Limited is an innovative biotechnology company based in Abingdon, UK, specializing in the development of advanced immunotherapies targeting cancer, infectious diseases, and autoimmune conditions. Leveraging its proprietary T cell receptor platform, Immunocore is dedicated to enhancing immune responses, thereby delivering transformative therapeutic options that aim to significantly improve patient outcomes. With a robust pipeline of clinical trials and strategic partnerships, the company is well-positioned for growth within the rapidly evolving immunotherapy landscape, presenting attractive opportunities for institutional investors seeking exposure in this critical sector.
Analyst Target Price
$66.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-26 | 2024-11-05 | 2024-08-08 | 2024-05-08 | 2024-02-28 | 2023-11-07 | 2023-08-10 | 2023-05-10 | 2023-03-01 |
| Reported EPS | -0.0035 | -0.2 | -0.49 | -0.3714 | 0.17 | -0.23 | -0.49 | -32.22 | 4 | -0.37 | -35 | -54 |
| Estimated EPS | -0.24 | -0.18 | -0.36 | -0.1594 | -0.35 | -0.48 | -0.36 | -21.74 | -28.92 | -32.1 | -32.19 | 0.03 |
| Surprise | 0.2365 | -0.02 | -0.13 | -0.212 | 0.52 | 0.25 | -0.13 | -10.48 | 32.92 | 31.73 | -2.81 | -54.03 |
| Surprise Percentage | 98.5417% | -11.1111% | -36.1111% | -132.9987% | 148.5714% | 52.0833% | -36.1111% | -48.2061% | 113.8313% | 98.8474% | -8.7294% | -180100% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IMCR
2026-02-10 12:28:47
Principal Financial Group Inc. reduced its stake in Immunocore Holdings PLC (NASDAQ:IMCR) by 9.6% in the third quarter of 2025, selling 43,510 shares to now own 411,409 shares valued at approximately $14.95 million. Despite this, other institutional investors have either increased their positions or initiated new ones in the company. Analysts currently rate Immunocore with a consensus "Moderate Buy" and a target price of $60.40, with the stock trading around $33.26 and having a market capitalization of $1.68 billion.
2026-02-09 14:28:31
Immunocore Holdings plc announced the departure of its Executive Vice President of R&D, Dr. David Berman, and will promote internal executives Dr. Mohammed Dar and Mark Moyer to expanded roles instead of hiring a direct replacement. This strategic shift aims to maintain continuity in clinical development and regulatory leadership, as the promoted executives have extensive experience with KIMMTRAK® and other therapies. The change could influence investor assessment of R&D execution and stability, with potential risks associated with a leaner structure affecting retention or the pace of new program advancement.
2026-02-03 11:31:00
Immunocore Holdings plc (IMCR) is a UK-based biotechnology company focused on developing immunotherapies for various diseases, boasting a robust pipeline and a market capitalization of $1.67 billion. Despite current negative EPS and free cash flow, analysts are highly optimistic, with 13 buy ratings and an average target price suggesting over 100% potential upside due to the company's innovative product KIMMTRAK and diverse pipeline. Technical indicators hint at a potential buying opportunity for investors looking into the biotech sector.
2026-02-03 10:58:25
Immunocore Holdings Plc (NASDAQ: IMCR) is experiencing volatility with weak near-term sentiment challenging long-term strength. AI models have generated three distinct trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Short Risk Hedging Strategy. The analysis indicates divergent sentiment across different time horizons, suggesting choppy conditions for the stock.
2026-02-01 05:27:53
Immunocore Holdings (NasdaqGS:IMCR) has announced a significant restructuring of its R&D leadership following Dr. David Berman's departure, with Dr. Mohammed Dar and Mark Moyer taking on expanded roles. This change comes as the company's shares are trading significantly below analyst targets and have seen substantial declines over the past three and five years. Investors are urged to monitor clinical timelines, regulatory interactions, and pipeline priorities as key indicators of the impact of these new leadership arrangements.
2026-01-31 07:31:46
Wall Street Zen downgraded Immunocore (NASDAQ:IMCR) from a "buy" to a "hold" rating following mixed Q4 results where the company beat EPS expectations but missed revenue estimates. Despite this downgrade, Immunocore maintains an average analyst rating of "Moderate Buy" with a consensus price target of $60.40. The company's stock opened at $32.55, with institutional investors showing varying interest in their holdings.
